Research programme: neurodegenerative disease therapies - RottapharmAlternative Names: CR-3391; CR-3394
Latest Information Update: 25 Feb 2010
At a glance
- Originator Rottapharm
- Class Small molecules
- Mechanism of Action Interleukin 6 inhibitors; NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease; Neurological disorders; Parkinson's disease
Most Recent Events
- 01 Mar 2006 Preclinical trials in Neurological disorders in Italy (unspecified route)
- 13 Oct 2005 Preclinical trials in Alzheimer's disease in Italy (unspecified route)